سعر ماتروكوند بلس قطرة عين 3مل 2022

Fixed combination of bimatoprost and timolol ophthalmic solution (3 ml) by Sigma Tec / Concord Pharmaceutical Industries, Egypt, for lowering intraocular pressure; strengths not stated by the sources opened.

• Reduction of intraocular pressure in adults with open-angle glaucoma or ocular hypertension insufficiently responsive to topical beta-blockers or prostaglandin analogues (UK GANFORT indication).Population: Adultselectronic medicines compendium (emc)

• Most common: conjunctival hyperaemia (about 26% at 12 months; mostly trace to mild). Common: headache, punctate keratitis, corneal erosion, burning or stinging, conjunctival irritation, eye pruritus, foreign body sensation, dry eye and eyelid erythema.General active-ingredient information · electronic medicines compendium (emc)

• Hypersensitivity to the active substances or any excipient.General active-ingredient information · electronic medicines compendium (emc)
• Reactive airway disease including bronchial asthma or a history of asthma, and severe chronic obstructive pulmonary disease.General active-ingredient information · electronic medicines compendium (emc)
• Sinus bradycardia, sick sinus syndrome, sino-atrial block, second or third degree AV block not controlled with a pacemaker, overt cardiac failure and cardiogenic shock.General active-ingredient information · electronic medicines compendium (emc)

• Timolol may be absorbed systemically and cause cardiovascular, pulmonary and other beta-blocker adverse reactions; assess patients with cardiovascular disease, use caution in first-degree heart block, severe peripheral circulatory disorders and mild/moderate COPD.General active-ingredient information · electronic medicines compendium (emc)
• Beta-blockers may mask signs of hypoglycaemia (labile diabetes) and of hyperthyroidism.General active-ingredient information · electronic medicines compendium (emc)
• Bimatoprost may cause eyelash growth, darkening of eyelid skin and increased (likely permanent) brown iris pigmentation; macular oedema has been reported; caution in active intraocular inflammation.General active-ingredient information · electronic medicines compendium (emc)

• Oral calcium channel blockers, guanethidine, beta-blockers, parasympathomimetics, anti-arrhythmics (including amiodarone), digitalis glycosidesPotential additive effects resulting in hypotension and/or marked bradycardia.electronic medicines compendium (emc)
• CYP2D6 inhibitors (e.g. quinidine, fluoxetine, paroxetine)Potentiated systemic beta-blockade (e.g. decreased heart rate, depression) has been reported with timolol.electronic medicines compendium (emc)
• Adrenaline (epinephrine)Mydriasis has occasionally been reported with ophthalmic beta-blockers and adrenaline.electronic medicines compendium (emc)

• No adequate data in pregnant women; should not be used during pregnancy unless clearly necessary. Oral beta-blockers carry a risk of intrauterine growth retardation, and beta-blockade signs may occur in the neonate if used until delivery.General active-ingredient information · electronic medicines compendium (emc)
• Should not be used by breast-feeding women (timolol is excreted in breast milk; bimatoprost is excreted in rat milk).General active-ingredient information · electronic medicines compendium (emc)

English text not available for this section.